Aktienanalyse zu Tarsus Pharmaceuticals Inc (TARS)TARSTarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Tarsus Pharmaceuticals Inc is a good buy right now due to its strong financial performance, including a gross margin of 93% and a projected revenue increase with Q2 sales reaching $173.9 million. The stock is currently priced at $71.76, with analysts setting a price target of $100, indicating a potential upside of 39%. The main risk is the negative net income of $18.55 million reported in Q2 2026, which investors should monitor closely.